Effect of 18 months elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosis
Valerie Taelman, Dimitri Declercq, Stéphanie Van Biervliet, Yannick Vande Weygaerde, Bruno Lapauw, Eva Van Braeckel
Topics & Concepts
MedicineIvacaftorCystic fibrosisCystic fibrosis-related diabetesBody mass indexGlycemicInternal medicineInsulinCohortDiabetes mellitusImpaired glucose toleranceEndocrinologyGastroenterologyCystic fibrosis transmembrane conductance regulatorInsulin resistanceCystic Fibrosis Research AdvancesAsthma and respiratory diseasesBiological Research and Disease Studies